Objectives: Ofloxacin and moxifloxacin are the most commonly used fluoroquinolones (FQs) for the treatment of tuberculosis. As a new generation FQ, moxifloxacin has been recommended for the treatment of ofloxacinresistant TB. However, the mechanism by which ofloxacin-resistant Mycobacterium tuberculosis further gains resistance to moxifloxacin remains unclear.
Introduction
Fluoroquinolones (FQs) are commonly used antibiotics for the TB, especially MDR-TB, i.e. TB caused by Mycobacterium tuberculosis strains resistant to the most effective first-line anti-TB drugs, isoniazid and rifampicin. As a third-generation FQ, ofloxacin is one of the most widely used second-line anti-TB drugs in recent decades. 1 FQs inactivate M. tuberculosis through targeting DNA gyrase, a type II topoisomerase composed of two A and two B subunits encoded by gyrA and gyrB, respectively.
2 M. tuberculosis can acquire resistance to FQs mainly through mutations in gyrA or gyrB, and this resistance then affects the whole class of FQs. 3, 4 In recent years, clinical resistance to ofloxacin (2 mg/L) due to gyrA/gyrB mutations has been widely reported; such resistance mainly occurred in MDR-TB cases and leads to the emergence of XDR-TB, i.e. MDR-TB with added resistance to an FQ and a second-line injectable drug. 5 Owing to the lack of effective drugs, the treatment of XDR-TB is still challenging. 6 The new-generation (i.e. fourth-generation) FQs, represented by moxifloxacin and gatifloxacin (the 8-methoxy FQs), have displayed enhanced lethality against M. tuberculosis compared with ofloxacin, both in vitro and in vivo. 7, 8 The MIC of moxifloxacin (0.25 mg/L) for WT M. tuberculosis is half, or less than half, that of ofloxacin (about 0.5 mg/L). [8] [9] [10] Although resistance through gyrA/ gyrB mutations affects the entire FQ class, the resistance level is lower for moxifloxacin (1-8 mg/L) than for ofloxacin (2-16 mg/L). [9] [10] [11] [12] [13] Consequently, many strains resistant to ofloxacin still have moxifloxacin MICs lower than its peak serum level (2-3 mg/L) under a daily dose of 400 mg. 14, 15 Therefore, WHO has recommended the inclusion of moxifloxacin in the treatment of XDR/pre-XDR TB patients despite the resistance to ofloxacin. 1, 16 V C The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
Several recent studies reported that moxifloxacin could improve treatment outcomes in ofloxacin-resistant MDR-TB cases. 17, 18 However, there was still a considerable number of cases that failed the treatment even when the initial ofloxacin-resistant strains were susceptible or had only low-level resistance to moxifloxacin, which may indicate further acquisition of moxifloxacin resistance during the treatment. Although gyrA/gyrB mutations selected by ofloxacin treatment cause cross-resistance to moxifloxacin, how M. tuberculosis with primary ofloxacin resistance further gains resistance to moxifloxacin is less well studied. An understanding of the mechanism is necessary to achieve early diagnosis of moxifloxacin resistance, which is of crucial importance for initiating effective treatment for XDR/pre-XDR TB cases. In the current study, we used Mycobacterium smegmatis as a model organism for studying moxifloxacin resistance in M. tuberculosis. M. smegmatis is genetically closely related to M. tuberculosis and has been shown to be highly consistent genetically with M. tuberculosis in mechanisms for rifampicin and ofloxacin resistance. 19, 20 We screened for moxifloxacin resistance based on primary ofloxacin-resistant strains and explored the potential mechanisms. We also evaluated the influence of identified mechanisms on bacterial fitness. Furthermore, we evaluated the clinical relevance of our findings by taking advantage of publicly available M. tuberculosis WGS data.
Materials and methods

Bacterial strains and growth conditions
All the resistant strains selected in current study were derived from the WT M. smegmatis strain MC 2 155. Bacteria were grown in Middlebrook 7H9 broth supplemented with 10% albumin, dextrose and catalase (ADC) or on Middlebrook 7H10 agar plates supplemented with 10% ADC. The culture tubes were incubated in standard conditions and the optical density (OD 600 ) was recorded to measure growth.
Selection of ofloxacin-and moxifloxacin-resistant M. smegmatis
Primary ofloxacin-resistant M. smegmatis strains were obtained as previously described. 20 Briefly, 16 groups of WT strain M. smegmatis MC 2 155 were cultured in Middlebrook 7H9 broth. When the bacteria reached the end of log phase, the cultures were centrifuged at 3000 rpm for 3 min; after discarding the supernatant, the bacteria were resuspended in 900 lL of Middlebrook 7H9 broth. Each of the concentrated bacterial cultures was plated onto Middlebrook 7H10 medium containing 2 mg/L ofloxacin (Sigma-Aldrich) and incubated for 3-5 days at 37 C for screening ofloxacinresistant colonies. One or two colonies (with different sizes) from each plate were picked and subcultured in antibiotic-free Middlebrook 7H9 broth. Similarly, ofloxacin-resistant M. smegmatis strains with different gyrA mutations were used for selection of moxifloxacin (2 mg/L) (Yuanye BioTechnique Co. Ltd., Shanghai) resistance.
DNA sequencing and mutation identification
DNA of the resistant colonies was extracted using a rapid boiling method as previously described. 21 The full-length sequences of FQ resistanceassociated genes gyrA and gyrB were amplified and sequenced using the following primers: for gyrA, gyrA-1F (5
. The sequences of each strain were aligned to the gyrA and gyrB genes of the reference strain MC 2 155 (GenBank, NC_008596) using Geneious (v9.0). Mutations were called if they were supported by both forward and reverse sequencing results. Mutations identified in gyrA and gyrB of M. smegmatis were transformed to corresponding codons in M. tuberculosis according to the numbering system proposed in 2002. 22 
MIC determination
MICs were primarily determined in Middlebrook 7H9 broth in 96-well plates, using a standard microdilution method. Serial 2-fold dilutions of ofloxacin/ moxifloxacin were prepared in 96-well plates. Each well was inoculated with 
In vitro competition assay and calculation of relative fitness
The screened mono-or double-mutation M. smegmatis strains were competed against the WT antibiotic-susceptible strain in pairs in Middlebrook 7H9 broth according to the procedure previously described. 20 Each M. smegmatis strain was cultured in 7H9 broth until its OD reached around 1.0. For baseline cfu counts, the culture was serially diluted to an OD of 10 #5 and then plated in triplicate onto 7H10-antibiotic-free media. For each WT-mutant strain pair, 200 lL portions of the diluted culture (OD " 10
#4
) of each strain were taken to inoculate 10 mL of 7H9 broth. After 72 h, the competition cultures were diluted 10 4 -to 10 5 -fold and plated on both selective (containing ofloxacin 2 mg/L) and non-selective (without drug) Middlebrook 7H10 media to obtain endpoint cfu counts. The experiment was carried out in three-parallel replicates for each WT-mutant strain pair. The Malthusian parameters for WT (m s ) and mutant (m r ) strains were calculated as the natural log of the ratio between the endpoint cfu and the starting cfu of each strain. The relative fitness of each mutant strain (W rs ) was calculated according to the formula W rs " m r /m s .
WGS data analysis
Short reads were firstly trimmed using Sickle (https://github.com/ucdavisbioinformatics/sickle) and were then mapped to the reference genome of H37Rv (GenBank, AL123456) with Bowtie2 (v2.2.6) using non-gapped alignments. Reads that mapped to more than one genomic position were discarded. VarScan2 (v2.3.6) was used to call SNPs (with frequency .5%) in drug resistance-associated genes. Strains that carried two or more mutations in the quinolone resistance-determining regions (QRDRs) of gyrA and gyrB were selected and gyrase double-mutation strains were further determined by viewing mapping profiles in IGV (v2.3.81) ( Figure S1 , available as Supplementary data at JAC Online). For the gyrase double-mutant strains, an SNP-calling and phylogenetic reconstruction pipeline was applied as follows. Genomic SNPs were called using the SAMtools/BCFtools suite; heterozygous calls and SNPs with coverage lower than three were filtered; SNPs in the PE/PPE, PE-PGRS and drug resistance-associated genes were also filtered; SNP lists for individual strains were combined into a single nonredundant list, and corresponding base calls were recovered for each strain.
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The concatenated sequences of the selected strains were used to generate a maximum likelihood (ML) phylogeny using MEGA5.
Results
Selection of ofloxacin-resistant M. smegmatis
A total of 26 M. smegmatis ofloxacin-resistant strains were obtained from 7H10 medium containing ofloxacin (2 mg/L) ( Table 1 ). All 26 strains harboured mutations in the QRDR of gyrA at codon 88, 90, 91 or 94. D94N, A90V and D94G were the most prevalent mutations, which is consistent with the clinical ofloxacin resistance of M. tuberculosis. 23 The MICs of ofloxacin for the 26 selected strains varied from 2.0 to 4.0 mg/L and were similar to those of clinical M. tuberculosis strains, the mutations in codon 94 were associated with higher MICs and mutations in codon 88, 90 and 91 were associated with lower MICs. There were at least 10-fold enhancements in the MICs of moxifloxacin for the 26 strains, confirming the cross-resistance between ofloxacin and moxifloxacin.
Mechanism of moxifloxacin resistance and the relative fitness of resistant strains
To study moxifloxacin resistance, we plated five isolates that primarily carried different mutations in gyrA codon 90, 91 or 94 onto 7H10 medium containing moxifloxacin (2 mg/L). A total of 57 moxifloxacin-resistant strains were screened and their mutation profiles in gyrA and gyrB were determined (Table 2) . Without exception, every moxifloxacin-resistant strain carried a secondary mutation in gyrA/gyrB, and, except for A126P, all the other mutations have been reported in clinical ofloxacin-resistant M. tuberculosis strains. 10, 23 The MICs of moxifloxacin for the 57 double-mutant strains varied from 4.0 to 6.0 mg/L, and were increased at least 4-fold compared with their mono-mutation parents. The MICs of ofloxacin for the double-mutation strains were also 2-to 6-fold higher, further confirming the cross-resistance between the two antibiotics.
According to the study by Borrell et al., 20 a single mutation in codon 90 or 94 of gyrA has little effect on the fitness of the bacteria. To evaluate the influence of double mutations on bacterial fitness, we firstly evaluated the growth rate of the doublemutation strains and their WT and mono-mutation parents. We found no or only a low decrease in growth rate in 7H9 broth for the mono-mutation strains compared with their WT parents. In contrast, many of the double-mutation strains showed a medium or large decrease in growth rate compared with their monomutation parents (Figure 1 ). However, there were several doublemutation strains (e.g. gyrA A90V ! D94G) showing little or no decrease in growth. Similar results were observed when plating the double-mutant strains (paired with the WT strain) onto 7H10 medium, on which the double-mutation strains with low growth rates formed smaller colonies compared with the WT (Figure S2) .
To quantify the influence of double mutations on the growth of bacteria, we further evaluated the relative fitness of mono-and double-mutation strains, in which the mutant strains were competed in vitro against their WT ancestor as described previously. 20, 24 We found that the mono-mutation strains showed small decreases in relative fitness compared with the WT (Figure 2 ). In contrast, most of the double-mutation strains displayed lower relative fitness when compared with their monomutation ancestors (P , 0.01). Only four strains with double mutations (gyrA A90V ! D94G, gyrA A90V ! D94N or gyrA D94H ! gyrB S504W) maintained relative fitness comparable to their monomutation parents.
Double mutations in DNA gyrase in clinical M. tuberculosis strains
To analyse gyrase double mutations in clinical M. tuberculosis, we evaluated their occurrence in a global collection of strains by taking advantage of WGS data that are publicly available. Highthroughput sequencing data provide valuable information to differentiate hetero-resistance (mixed strain sub-populations with different mutations) and real double mutations ( Figure S1 ). When mutations are closely located, a double mutation could be confirmed when they were found in the same sequence read; for mutations that are distantly located, if one mutation is fixed (homozygous mutation, with an allelic frequency of 100%) and the other mutation(s) is unfixed/fixed (heterozygous/homozygous mutation, with an allelic frequency from 5% to 100%), a double mutation could be confirmed. As ofloxacin resistance mainly happened in MDR M. tuberculosis, we included three WGS projects (TB-ARC, SRP017938 and SRP058221) containing 1984 strains that are mainly MDR 25, 26 (and https://olive.broadinstitute.org/projects/ tb_arc), and we analysed the mutation profiles of gyrA and gyrB in Gyrase double mutation and moxifloxacin resistance JAC Luo et al.
these strains. We identified 37 lineage 2/lineage 4 strains from six countries that carried at least two mutations in the QRDR of gyrA and/or gyrB ( Figure 3 ). Except for one strain, all the other strains were MDR and all strains were resistant to at least four anti-TB drugs as predicted from resistance-associated genes. Furthermore, 24 strains were XDR and 16 of them were resistant to all first-and second-line drugs. A total of 24 double-mutation patterns (isolates with more than one heterozygous mutation were treated as several double mutants) and one triple-mutation pattern were identified. Five mutation patterns overlapped with the laboratory-derived M. smegmatis (gyrA A90V ! D94G, three strains; gyrA A90V ! S91P, five strains; gyrA S91P ! D94G, one strain; gyrA D94G ! gyrB T500N, two strains; gyrA D94G ! gyrB N499T, two strains), and all of them showed relative high fitness (м0.81) in M. smegmatis. There were nine strains carrying one homozygous mutation and another carrying one or more heterozygous mutations in the QRDR of gyrA and/or gyrB, which indicates ongoing acquisition of secondary mutation(s).
Discussion
Being a fast grower and non-pathogenic, M. smegmatis is commonly used for studying the pathogeny and drug resistance of M. tuberculosis. 20, 27 In the current study, we used M. smegmatis to study FQ resistance of M. tuberculosis, and we found that a secondary mutation in DNA gyrase is the exclusive mechanism by which M. smegmatis acquires moxifloxacin resistance based on primary resistance to ofloxacin. The primarily screened ofloxacin-resistant M. smegmatis strains harboured gyrA mutations that were prevalent in clinical M. tuberculosis strains; furthermore, the resistance levels (high or low) to ofloxacin for different mutations in M. smegmatis were highly concordant with those in M. tuberculosis. For the 57 double-mutant M. smegmatis strains obtained by screening against moxifloxacin, most (56/57) carried secondary mutations that had been reported in clinical FQ-resistant M. tuberculosis strains. The remaining strain carried a secondary mutation (gyrA A126P) that had not reported previously; however, an alternative mutation, A126R, at this locus had been identified in several clinical ofloxacin-resistant M. tuberculosis strains. 13, 28 Taking these results together, the mutations identified in M. smegmatis are highly concordant with clinical M. tuberculosis strains, which shows that M. smegmatis is a reliable model for studying FQ resistance of M. tuberculosis.
The QRDRs of gyrA and gyrB both locate in the quinolonebinding pocket (QBP) and mutations in these regions could influence the interaction between FQ and gyrase. 29, 30 Mutations in the gyrA QRDR (e.g. gyrA D94G) lead to FQ resistance through changing the conformation of the QBP and directly or indirectly blocking the formation of the water-metal ion bridge. 31 Double mutations in this region may lead to larger steric hindrance for the interaction between FQs and the QBP, which then causes high-level FQ resistance. The gyrB QRDR contains residues interacting with the R7 group of FQs probably through a complementary van der Waal's Gyrase double mutation and moxifloxacin resistance JAC surface, and mutations in this region may change such a surface and prohibit the localization of the FQ in the QBP. 29, 30 Combination of mutations in both QRDRs would affect both the formation of water-metal ion bridges and the interaction between the FQ R7 group and the QBP, which ultimately leads to high-level FQ resistance.
M. tuberculosis strains with multiple mutations in gyrA and/or gyrB have been reported in several previous studies. 9, 10, 12, 13, [32] [33] [34] [35] However, multiple mutations detected in clinical samples may indicate hetero-resistance (mixed strain sub-populations with different mutations) or real double-/multi-mutations and few studies differentiated the two. 10, 12, 32 Even so, many studies reported high-level ofloxacin resistance among isolates identified with multiple mutations in gyrA and/or gyrB. 9, 10, 32, 34 Several studies tested the MIC of moxifloxacin for isolates with multiple gyrase mutations, and high-level (.2 mg/L) moxifloxacin resistance was detected for isolates with several gyrase double mutations (e.g. gyrA A90V and D94G, gyrA S91P and D94G, and gyrA D94A and gyrB N499T), 9, 12, 35 which suggests an association between gyrase double mutations and moxifloxacin resistance for clinical M. tuberculosis. As a further proof, Poissy et al.
14 used moxifloxacin to treat primary ofloxacin-resistant M. tuberculosis (with different gyrA/gyrB mutations) in a murine model and they obtained several strains (with primary mutations of gyrB D500N or gyrA A90V) that harboured secondary mutations in gyrA, suggesting the selection of double-mutation strains under the pressure of moxifloxacin. Taking these findings together, double mutations in DNA gyrase resulted in moxifloxacin resistance both in the laboratory and in clinical mycobacteria.
Clinically, the most frequently occurring FQ resistance mutations are located in gyrA codon 94 (e.g. D94G, D94A and D94N), and mutations in gyrB are less common. 10, 23 However, among the 37 double-mutation M. tuberculosis strains identified in this study, 51.4% (19/37) carried mutation A90V and 73.0% (27/37) carried gyrB mutations. Interestingly, almost all strains (36/37) harboured at least one homozygous mutation that was associated with lowlevel FQ resistance, i.e. gyrA G88A, gyrA A90V/G, gyrB N499S/T and gyrB T500N. 3, [36] [37] [38] One possible explanation is that double mutations in DNA gyrase mainly happened in clinical strains that primarily carry low-level resistance mutations. As further proof, there were nine isolates harbouring a homozygous mutation and at least one heterozygous mutation, which suggests the corresponding strains harboured a primary mutation (the homozygous mutation) and an emerging secondary mutation(s) (the heterozygous mutation), respectively. Among them, the primary mutations of eight strains were associated with low-level resistance (i.e. gyrA A90V, gyrA S91P, gyrA G88A, gyrB D500N and gyrB N499S).
In the current study there were 30 M. smegmatis strains harbouring secondary mutations in gyrB, and most of them (28/30) harboured a primary mutation in gyrA codon 94 (Table 2 ). Furthermore, almost all (29/30) the gyrB mutations happened in codons 499 and 501, and the mutations were mainly N499K (18 strains) and E501D (7 strains), which were rarely reported in clinical M. tuberculosis strains. 10, 23 Recently, several studies found that mutations N499K and E501D only conferred resistance to moxifloxacin but not to other FQs. 11, 39 Furthermore, in an earlier study by Joyce Barrozo et al., 40 laboratory-derived M. tuberculosis strains harbouring these two mutations were obtained by screening FQ-susceptible M. tuberculosis against moxifloxacin in vitro. The exclusive resistance to moxifloxacin conferred by mutations N499K and E501D may be associated with the R7 group (azabicyclo), which is much larger than that of ciprofloxacin (piperazine) or ofloxacin/levofloxacin (methylpiperazine). Since both mutations lead to change in the side chain length of the corresponding residue in the QBP, the accommodation of the azabicyclo of moxifloxacin may be interrupted while that of the ofloxacin/ levofloxacin was less affected.
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Although mutations N499K and E501D are commonly obtained in laboratory-derived M. tuberculosis/M. smegmatis strains, they were rarely reported in clinical settings, 10, 23 which may be associated with the current regimen and dosing of moxifloxacin. Moxifloxacin is currently mostly used for the treatment of ofloxacin-resistant cases with a daily dose of 400 mg, which would result in a maximum serum concentration of 2-3 mg/L. 14, 15 In our experiment, N499K and E501D mainly co-occurred with high-level resistance mutations in gyrA codon 94. For clinical M. tuberculosis, mutations in gyrA codon 94 could lead to high-level moxifloxacin resistance: MIC 4 mg/L, which is higher than the maximum serum concentration. 11, 12, 38, 41 Therefore, such M. tuberculosis strains may not need to further accumulate mutations to resist current clinical doses of moxifloxacin. For instance, Poissy et al.
14 only identified secondary mutations among strains with primary low-level resistance mutations (i.e. gyrB D500N or gyrA A90V), and no additional mutation was found in strains with mutation gyrA D94G. Alternatively, mutations N499K and E501D of gyrB may cause a high fitness cost in clinical M. tuberculosis and may have been suppressed during competition with other resistant mutants. As an example, the fitnesses of several M. smegmatis double mutants with gyrB N499K or E501D mutations (i.e. gyrA D94N and gyrB N499K, gyrA D94N and gyrB E501D, and gyrA D94H and gyrB E501D) were among the lowest in the screened strains (Figure 2 ). In contrast, the five mutation patterns that overlapped between laboratory-derived M. smegmatis and clinical M. tuberculosis conferred relatively low fitness costs in M. smegmatis, suggesting theselection of high-fitness moxifloxacin-resistant strains in clinical M. tuberculosis. However, whether all/most of the remaining 20 double-/triple-mutant patterns identified in clinical M. tuberculosis confer high fitness needs to be further verified.
In summary, we found that double mutations in DNA gyrase led to moxifloxacin resistance and decreased fitness in M. smegmatis. Under the current regimen and dosing of moxifloxacin, double mutations mainly occurred in clinical M. tuberculosis strains with primary low-level FQ resistance mutations and M. tuberculosis might be prone to selection of double mutations with low fitness cost. Further studies are needed to validate the association between gyrase double mutations observed in clinical strains and moxifloxacin resistance in M. tuberculosis and evaluate their effects on bacterial fitness.
